# A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

> **NCT05629585** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 1174 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Dato-DXd
- **DRUG:** Durvalumab
- **DRUG:** Capecitabine
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05629585
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-11-28
- **Primary completion:** 2027-09-20
- **Final completion:** 2030-01-30
- **Target enrollment:** 1174 (ACTUAL)
- **Last updated:** 2026-03-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05629585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05629585, "A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05629585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*